Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplant

NCT03413800 is registered in ClinicalTrials.gov with Ciusss de L'Est de l'Île de Montréal as lead sponsor.

NCT NCT03413800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03413800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplant
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2018
Completion date
March 27, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapsed hematologic malignancy